HTA Database - Search Results

Sort by Relevance

Search Results [146 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	Belgian Health Care Knowledge Centre (KCE)	Cost-effectiveness of maternal immunisation by Abrysvo® or a single injection of a monoclonal antibody (Beyfortus®) in infants for infant protection against infection by the respiratory syncytial virus in Belgium (Study 2024-51)
2025	Health Information and Quality Authority (HIQA)	Protocol for a health technology assessment of immunisation against respiratory syncytial virus in Ireland
2025	NIHR Health Technology Assessment programme	Lessons from the PROTECT-CH COVID-19 platform trial in care homes
2025	Agency for Care Effectiveness (ACE)	Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2024	Health Information and Quality Authority (HIQA)	Enhanced inactivated influenza vaccines for over 65s: protocol for a health technology assessment
2024	NIHR Health Technology Assessment programme	Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis
2024	Canary Health Service	[Cost-effectiveness of universal vaccination against pneumococcal disease with the new conjugate vaccines against 15 and 20 serotypes]
2024	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of immunisation against respiratory syncytial virus (RSV) in Ireland
2024	WorkSafeBC	Causal association on the development of trigeminal neuralgia post covid-19 vaccine
2023	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of the extension of the seasonal influenza vaccination programme to include those aged 50 to 64 years (general population)
2023	WorkSafeBC	Migraines and the (Moderna) COVID-19 vaccine
2023	WorkSafeBC	Myalgic encephalomyelitis/chronic fatigue syndrome associated with mRNA COVID-19 vaccination
2023	Center for Drug Evaluation (CDE)	[Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023	Center for Drug Evaluation (CDE)	[Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2023	Canary Health Service	[Cost-effectiveness of systematic vaccination against invasive meningococcal disease due to serogroup B in childhood]
2023	Canary Health Service	[Cost-effectiveness of childhood vaccination against invasive meningococcal disease due to ACWY serogroups]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: KamRAB (human rabies immunoglobulin) – passive and transient postexposure prophylaxis of rabies infection]
2022	WorkSafeBC	Tinnitus and the COVID-19 vaccine
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Achieving safe surgery after COVID-19 vaccination
2022	Canary Health Service	[Influenza vaccination in children 6 to 59 months of age]
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Evaluation of several vaccination strategies against rotavirus in Spain. Safety, efficacy, effectiveness and efficiency]
2021	Health Council of the Netherlands Gezondheidsraad (GR)	[Influenza vaccination: review of indications]
2021	NIHR Health Technology Assessment programme	A Phase II randomised clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with dendritic cells pulsed with HepG2 lysate ex vivo in patients with Hepatocellular Carcinoma: IMMUNOTACE
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: thrombotic adverse events with adenovirus vaccines
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: vaccination for women who are pregnant or lactating
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: management of vaccine-associated thrombotic syndromes
2021	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of 13-valent pneumococcal conjugate vaccine (Prevenar13®) for medical high-risk groups
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Influence of COVID-19 vaccines on surgical practice
2021	Agency for Healthcare Research and Quality (AHRQ)	Safety of vaccines used for routine immunization in the United States: an update
2021	Health Information and Quality Authority (HIQA)	Duration of protective immunity following COVID-19 vaccination (efficacy and effectiveness)
2021	Health Information and Quality Authority (HIQA)	Evidence synthesis for groups in vaccine allocation group nine - those aged 18-64 years living or working in crowded conditions
2020	NIHR Health Technology Assessment programme	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
2020	NIHR Health Technology Assessment programme	Seasonal Influenza Vaccination Effectiveness II (SIVE II): use of a large national primary care and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 1; Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 2 (Appendix)
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with oral cholera vaccination
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Adverse effects of messenger RNA vaccines
2020	Malaysian Health Technology Assessment (MaHTAS)	Influenza vaccination for the elderly and economic evaluation
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Human papilloma virus (HPV) vaccine in patients with HPV lesions or infection]
2020	Malaysian Health Technology Assessment (MaHTAS)	Strategies to eliminate mother to child transmission of hepatitis B in Malaysia
2020	Malaysian Health Technology Assessment (MaHTAS)	Pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) for elderly
2020	Canary Health Service	[Cost-effectiveness of universal childhood vaccination against hepatitis A (update)]
2020	National Authority for Assessment and Accreditation in Healthcare (INEAS)	Vaccination contre la grippe dans le contexte particulier de la pandémie COVID-19 : intérêt et populations prioritaires
2020	Canary Health Service	[HPV vaccination in adolescent boys: cost-effectiveness and budget impact]
2020	Health Information and Quality Authority (HIQA)	Evidence summary of the immune response following infection with SARS-CoV-2 or other human coronaviruses
2020	Health Information and Quality Authority (HIQA)	Factors influencing, and measures to improve, vaccination uptake: rapid evidence summary
2020	Health Information and Quality Authority (HIQA)	Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over
2020	Health Information and Quality Authority (HIQA)	Scoping report: universal influenza vaccination in children
2019	Belgian Health Care Knowledge Centre (KCE)	Cost-effectiveness analysis of HPV vaccination of boys in Belgium
2019	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with influenza vaccination
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[4CMenB vaccine for primary vaccination]
2019	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	Medicinsk teknologivurdering (MTV) af HPV vaccination til drenge
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use guide: herpes simplex eye disease]
2018	Health Information and Quality Authority (HIQA)	Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys
2017	NIHR Health Technology Assessment programme	Observational study to estimate the changes in the effectiveness of bacillus Calmette Guerin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK
2017	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with HPV vaccination
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[CYD tetravalent dengue vaccine]
2017	Canary Health Service	[Cost-effectiveness of pneumococcal vaccination in adults older than 60 years]
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Remestemcel-L for graft vs host disease in paediatric patients – second line
2016	Belgian Health Care Knowledge Centre (KCE)	Use of pneumococcal vaccines in the elderly an economic evaluation
2015	NIHR Health Technology Assessment programme	Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Rindopepimut for EGFRvIII positive glioblastoma multiforme - first line
2015	NIHR Health Technology Assessment programme	Vaccines for preventing influenza in healthy adults (A060)
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Remestemcel-L (Prochymal) for steroid refractory acute graft versus host disease – second line
2015	Andalusian Health Technology Assessment Area (AETSA)	Active immunotherapy for lung cancer. Systematic review.
2015	Norwegian Institute of Public Health (NIPH)	Cost-effectiveness of HPV-vaccination of boys aged 12 in a Norwegian setting
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sipuleucel-T (Addendum to Commission A14-38)]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Conjugate pneumococcal vaccine (13-Valent) for immunocompromised populations: a review of the clinical evidence
2014	Health Council of the Netherlands Gezondheidsraad (GR)	Fighting the flu
2014	Agency for Healthcare Research and Quality (AHRQ)	Safety of vaccines used for routine immunization in the United States
2014	Belgian Health Care Knowledge Centre (KCE)	A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study
2014	Malaysian Health Technology Assessment (MaHTAS)	Pneumococcal conjugate vaccine for children below five years old
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sipuleucel-T - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Cost-effectiveness of human papillomavirus vaccination in South Korea]
2013	Belgian Health Care Knowledge Centre (KCE)	Seasonal influenza vaccination: prioritizing children or other target groups? Part II: cost-effectiveness analysis
2012	Medical Advisory Secretariat (MAS)	Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review
2012	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Rotavirus vaccination - a health technology assessment]
2012	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Economic evaluation of the introduction of the HPV vaccine in Spain to prevent cervical cancer]
2012	Belgian Health Care Knowledge Centre (KCE)	Vaccine safety surveillance in Belgium : place and limits of a background rate approach
2011	Health Council of the Netherlands Gezondheidsraad (GR)	[Population screening for cervical cancer]
2011	Belgian Health Care Knowledge Centre (KCE)	Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood
2011	NIHR Health Technology Assessment programme	A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children
2011	HAYES, Inc.	Intranasal trivalent live attenuated influenza vaccine
2011	Andalusian Health Technology Assessment Area (AETSA)	[Vaccine against Neisseria meningitidis serogroup B]
2011	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Cost-utility analysis of the introduction of universal infant rotavirus vaccination in Spain]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy and safety of active immunotherapy in HIV-infected adults. Therapeutic vaccines against HIV.]
2010	NIHR Health Technology Assessment programme	Exploring the needs, concerns and behaviours of people with existing respiratory conditions in relation to the H1N1 swine influenza pandemic: a multicentre survey and qualitative study
2010	Institute for Clinical Effectiveness and Health Policy (IECS)	Pandemic Influenza A Vaccine (H1N1)
2010	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Economic evaluation of a pneumococcal vaccination program in a pediatric population]
2010	NIHR Health Technology Assessment programme	Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion- adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age
2010	Belgian Health Care Knowledge Centre (KCE)	[Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium]
2010	NIHR Health Technology Assessment programme	Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy
2010	NIHR Health Technology Assessment programme	A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart
2010	NIHR Horizon Scanning Centre (NIHR HSC)	OncoVEX GM-CSF for unresectable metastatic melanoma - first and second line treatment
2010	Andalusian Health Technology Assessment Area (AETSA)	[Immunisation against angiotensin II. A therapeutic vaccine against arterial hypertension]
2010	National Evidence-based Healthcare Collaborating Agency (NECA)	[The disease burden of seasonal influenza and the effectiveness of seasonal influenza vaccination in Korea]
2009	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors]
2009	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Developing a decision aid on HPV-vaccination for young girls and women/ mothers
2009	Norwegian Knowledge Centre for the Health Services (NOKC)	Influenza vaccination of elderly and people with chronic illness
2009	Norwegian Knowledge Centre for the Health Services (NOKC)	[Cost-effectiveness of childhood vaccination against rotavirus in Norway]
2008	The Swedish Council on Health Technology Assessment (SBU)	[General childhood vaccination against HPV 16 and 18 aimed at preventing cervical cancer]